title: In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
abstract: In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs (acyloxyalkoxy-based cyclic prodrug of DADLE, coumarinic acid-based cyclic prodrug of DADLE, and oxymethyl-modified coumarinic acid-based cyclic prodrug of DADLE) were conducted. The enzymatic stability of DADLE and its prodrugs in various biological media was determined at 37 degrees C in the presence and absence of paraoxon, a known esterase inhibitor. The prodrugs exhibited metabolic stability to exo- and endopeptidases, and esterase-catalyzed bioconversion of the prodrugs to DADLE was observed. For pharmacokinetic studies in rats, various biological samples (blood, bile, urine, and brain) were collected after i.v. administration of DADLE and its prodrugs. The samples were analyzed by high-performance liquid chromatography with tandem mass spectrometric detection, and the conversion from the prodrugs to intermediates to DADLE was monitored. The prodrugs exhibited similar pharmacokinetic properties and showed improved stability compared with DADLE in rat blood. This increased stability led to higher plasma concentrations of DADLE after i.v. administration of the prodrugs compared with i.v. administration of DADLE alone. In terms of elimination pathways, metabolism by endopeptidases was the major route for DADLE elimination, whereas rapid biliary excretion was the major route of elimination for the prodrugs. The rapid elimination of the prodrugs by the liver and the formation of stable intermediates after esterase hydrolysis limited the bioconversion efficiencies of the prodrugs to DADLE after i.v. administration. The substrate activity of the prodrugs for efflux transporters (e.g., P-glycoprotein) in the blood-brain barrier significantly restricted their access to the brain.
authors.affiliation: Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, KS 66047, USA.
authors.forename: Jerry Z
authors.initials: JZ
authors.lastname: Yang
authors.forename: Weiqing
authors.initials: W
authors.lastname: Chen
authors.forename: Ronald T
authors.initials: RT
authors.lastname: Borchardt
mesh_terms: D000818:Animals; D001702:Biopharmaceutics; D001711:Biotransformation; D001798:Blood Proteins / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D003500:Cyclization; D004355:Drug Stability; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives / Q000737:chemistry* / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism; D008297:Male; D009294:Narcotics / Q000737:chemistry* / Q000493:pharmacokinetics*; D011355:Prodrugs / Q000737:chemistry* / Q000493:pharmacokinetics*; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D001798:Blood Proteins; D009294:Narcotics; D011355:Prodrugs; D016308:Enkephalin, Leucine-2-Alanine